Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Pharmacog. polym. & drug metab.
- (P. I) Psychopharmacology and pain
- Clinical pharmacogenomics
- Genetic variability of drug response
- Genetic variability in pharmacokin.
- Polymorphisms in drug metabolism
- Genetics-based dose adjustments
- Polymorphic drug metab. enzymes
- CYP2D6 - activity in Caucasians
- Variability in doxepin kinetics
- Antidep. drug treat. - problems
- CYP2D6 in antidep. drug treat.
- CYP2D6 polym. - antidep. drug treat.
- CYP2D6-based dose adjustments
- Genotype-based dose adjustments
- Genotype-phenotype interaction
- CYP2D6 interethnic differences
- Influence of polymorphisms in DME
- Types of adverse drug reactions
- Antidepressant drug treatment
- CYP2D6 geno. in ADR patients
- Adverse effect of antipsychotics
- CYP2D6 and haloperidol clearance
- Extrapyramidal sympt. & CYP2D6
- CYP2D6 - not just a DME
- CYP2D6 in psychiatry - summary
- PG polymorphisms in DME
- Codeine
- Morphine conc. after codeine treat.
- CYP2D6 sedat. after codeine treat.
- Tramadol
- PG polymorphisms in DME
- Metabolism of NSAIDs
- CYP2C genetic locus
- CYP2C9
- CYP2C9 - pharmacok. of ibuprofen
- CYP2C9 - prostaglandin E2
- CYP2C9 - COX-1 inhibition
- CYP2C9 - PK differences of NSAIDs
- Physiologic role of CYP2C8/9
- CYP inhibitors
- Conclusion (pain)
- Acknowledgments
Topics Covered
- Pharmacogenetic polymorphisms
- Biotransformation and clinical outcome
- Consequences of genotyping
- Feasibility for genotyping in antidepressant drug treatment
- Polymorphic cytochrome P450 enzyme CYP2D6
- Feasibility for genotyping in pain treatment
- CYP2C9, CYP2D6 and nonsteroidal analgetic drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stingl (formerly Kirchheiner), J. (2007, October 1). Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 11, 2024, from https://doi.org/10.69645/OUON8575.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Julia Stingl (formerly Kirchheiner) has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain
A selection of talks on Neuroscience
Hide